Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Idiopathic Hypersomnia

Idiopathic Hypersomnia

Part of Sleep Disorders, Intrinsic

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Idiopathic Hypersomnia

5 trials tracked for Idiopathic Hypersomnia: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 67 citations.

5Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 3 Phase 1 1
  1. Phase 3 A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension Completed · 67 cited
  2. Phase 2 Clarithromycin for the Treatment of Hypersomnia Completed
  3. Phase 2 Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia Completed
  4. Phase 2 Flumazenil for the Treatment of Primary Hypersomnia Completed
  5. Phase 1 A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Idiopathic Hypersomnia: what the trials found

Clinical evidence for Idiopathic Hypersomnia includes data from a Phase 3 trial evaluating JZP-258 (N=154). In this study, the mean change in Epworth Sleepiness Scale (ESS) score was 0.7 compared to 7.4 in the control group 1.

In the same Phase 3 trial, the Idiopathic Hypersomnia Severity Scale (IHSS) showed a mean change of 0.0 for JZP-258 versus 14.0 for the comparator 1. Additionally, 12% of participants in the JZP-258 group reported being worse on the Patient Global Impression of Change (PGIc), compared to 52% in the control group 1.

Recent results — preliminary, needs further review

  • Modafinil showed a mean change in ESS score of 5.0 vs 4.4 in a Phase 2 trial (N=44) 2.
  • Clarithromycin followed by placebo did not show statistically significant improvements in Psychomotor Vigilance Task (PVT) reaction times or lapse numbers (p=0.47, p=0.63, and p=0.64 respectively) in a Phase 2 trial (N=26) 3.
  • Flumazenil did not show statistically significant changes in PVT median reaction time (p=0.77), lapse frequency (p=0.51), or duration of lapse domain (p=0.32) in a Phase 2 trial (N=10) 4.
  • TAK-925 was evaluated in a Phase 1 trial (N=28), where 14.8% of participants experienced at least one treatment-emergent adverse event (TEAE) 5.

For the clinician treating this condition

  • JZP-258 demonstrated a lower rate of patients reporting worse outcomes on the PGIc compared to control, and showed a mean change in ESS score of 0.7 1.
  • JZP-258 was associated with an IHSS mean change of 0.0 compared to 14.0 in the comparator group 1.

AI synthesis of 5 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Observational study finds autonomic dysfunction in idiopathic hypersomnia versus narcolepsy and controls
Neurology
Observational study finds autonomic dysfunction in idiopathic hypersomnia versus narcolepsy and controls Do you feel exhausted all day? New data shows your heart may struggle when you stand up
This observational study assessed autonomic nervous system function in adults with idiopathic hypersomnia (IH), type 1 narcolepsy (NT1), and…
People with idiopathic hypersomnia have hearts that race faster when standing and struggle to sweat properly, revealing hidden autonomic ner…
medRxiv Apr 16, 2026